title: Role of plasminogen activators during healing after uterine serosal lesioning in the rat.
abstract: OBJECTIVE
  Study the expression pattern of tissue-type (t-PA) and urokinase-type (u-PA) plasminogen activators during uterine serosal healing after lesioning in a rat model.
  
  
  METHODS
  Descriptive study with an adhesion model using reverse transcriptase-polymerase chain reaction (PCR) and immuncytochemical techniques.
  
  
  METHODS
  Academic medical center.
  
  
  METHODS
  None.
  
  
  METHODS
  None.
  
  
  METHODS
  Expression profiles of t-PA and u-PA were examined in the uteroperitoneal adhesion tissues of rat from the time of injury until day 7 after surgery using relative abundance reverse transcriptase-PCR and immunocytochemical techniques.
  
  
  RESULTS
  The t-PA transcript levels dropped in uteroperitoneal tissues by 6 hours after surgery and remained low until day 5. Thereafter, a rapid up-regulation of this transcript was observed at day 7. In contrast, the u-PA transcript levels demonstrated a biphasic profile during the progression of adhesion development with peaks at 2 and 5 days after surgery. Immunocytochemical staining demonstrated expression of these plasminogen activators in the newly formed blood vessels.
  
  
  CONCLUSIONS
  Altered levels of t-PA and u-PA transcripts and its expression in newly formed blood vessels during healing and adhesion development indicate involvement of these plasminogen activators in serosal healing and adhesion development.
authors.affiliation: C. S. Mott Center for Human Growth and Development, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA. aa4306@wayne.edu
authors.forename: Ujjwal Kumar
authors.initials: UK
authors.lastname: Rout
authors.forename: Michael P
authors.initials: MP
authors.lastname: Diamond
mesh_terms: D000818:Animals; D005260:Female; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000235:genetics; D007150:Immunohistochemistry; D010532:Peritoneal Diseases / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D010960:Plasminogen Activators / Q000502:physiology*; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000267:Tissue Adhesions / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D010959:Tissue Plasminogen Activator / Q000032:analysis / Q000235:genetics / Q000502:physiology; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis / Q000235:genetics / Q000502:physiology; D014591:Uterine Diseases / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D014599:Uterus / Q000601:surgery*; D014945:Wound Healing / Q000502:physiology*
chemical_list: D012333:RNA, Messenger; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator